EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Zinc and copper target molecular complexity and revert endometriosis phenotypes being a promising therapy for disease progression and infertility

Pablo Garcia-Acero, Francisco Jose Sanz, Patricia Sebastian-Leon, Almudena Devesa-Peiro, Antonio Parraga-Leo, Patricia Diaz-Gimeno iD

Reproduction and Fertility · 06.11.2026

DOI: 10.1530/raf-26-0060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reproduction and Fertility, online erschienen am 06.11.2026. Verfasst von Pablo Garcia-Acero und 5 weiteren Autor:innen. Beteiligte Einrichtung: IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Av. Fernando Abril Martorell 106, Torre A, P…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatments of endometriosis, a complex and polygenic disease characterized by the growth of endometrial-like tissue outside the uterus, are ineffective in many patients and prone of side effects. Systems pharmacology development offered new avenues to study complex diseases at a systematic level for prioritizing more effective therapies. Here, we apply this strategy for gene disease and drug prioritization by using six gene expression datasets from Gene Expression Omnibus of healthy, eutopic and ectopic endometrium. A similar molecular basis of endometriosis disease and infertility-associated genes was highlighted since they share a gene overlap higher than randomly expected (210 genes through direct protein-protein interactions from 553 infertility-related and 2,931 endometriosis disease-related genes, p-value=1.9 × 10-11) and these genes were closer physically interacting in the network than random expectation (z-score=-1.75, p-value=0.03). Sixteen potential candidate drugs were identified, which had superior molecular efficacy treating the disease as they target more endometriosis-related genes (p-value=0.01) than randomly expected compared with current treatments (p-value=0.97). Zinc, copper and resveratrol, which were found among the clinically safest candidate compounds, suppressed endometriosis-related phenotypes in endometriosis cells (cell proliferation, migration, and overexpression of endometriosis-related biomarkers). This systems pharmacology approach, together with the in vitro validation in the endometriosis cell model, allowed to identify zinc and copper, nutraceutical compounds, as potential endometriosis treatments addressing the causes of the disease rather than symptoms like current therapies. Additionally, since both compounds are already approved for other indications, they can be proposed for repurposing for endometriosis therapies, reducing time and costs of clinical trials. Lay Summary Current treatments for endometriosis address symptoms rather than causes, are not always effective, and produce side effects. We used a computer-based approach to compare gene expression in healthy endometrial tissue and in endometrial tissue affected by endometriosis. This helped us identify which genes may be involved in the disease and which existing drugs might be worth testing as possible treatments. We found that endometriosis disease and infertility-associated genes share similarities, suggesting that both conditions may have similar underlying causes. We looked for existing drugs and compounds that might target those underlying causes more effectively than current treatments. We found that zinc and copper might be promising treatments for endometriosis because they may target the disease’s underlying causes. Since these drugs are already used for other purposes, repurposing them may reduce the time and cost of clinical trials.

Schlagwörter

Stichwörter der Autor:innen

CopperDrug repurposingEndometriosisSystems pharmacologyWomen´s reproductive healthZinc

Autor:innen und Institutionen

  • IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Av. Fernando Abril Martorell 106, Torre A, Planta 1a , Valencia, Spain.
  • Department of Pediatrics, Obstetrics, and Gynecology, University of Valencia, Av. Blasco Ibáñez 15 , Valencia, Spain.

ORCID-Profile: Patricia Diaz-Gimeno

Zitieren

APA

Garcia-Acero, P., Sanz, F. J., Sebastian-Leon, P., Devesa-Peiro, A., Parraga-Leo, A., & Diaz-Gimeno, P. (2026). Zinc and copper target molecular complexity and revert endometriosis phenotypes being a promising therapy for disease progression and infertility. Reproduction and Fertility. https://doi.org/10.1530/raf-26-0060

Vancouver

Garcia-Acero P, Sanz FJ, Sebastian-Leon P, Devesa-Peiro A, Parraga-Leo A, Diaz-Gimeno P. Zinc and copper target molecular complexity and revert endometriosis phenotypes being a promising therapy for disease progression and infertility. Reproduction and Fertility. 2026. doi:10.1530/raf-26-0060

BibTeX
@article{GarciaAcero2026,
  author = {Garcia-Acero, Pablo and Sanz, Francisco Jose and Sebastian-Leon, Patricia and Devesa-Peiro, Almudena and Parraga-Leo, Antonio and Diaz-Gimeno, Patricia},
  title = {Zinc and copper target molecular complexity and revert endometriosis phenotypes being a promising therapy for disease progression and infertility},
  journal = {Reproduction and Fertility},
  year = {2026},
  doi = {10.1530/raf-26-0060}
}
Kostenlos starten →